None listed
Conditions
Brief summary
Quinidine is the only drug shown to reduce the risk of dangerous irregular heart rhythms in Brugada Syndrome. While studies have shown invasive electrophysiology studies can be useful in assessing response to quinidine in Brugada Syndrome, currently, there is no definitive way to monitor drug effect in an individual. The QUIET BrS Study will investigate the effect of quinidine on a variety of clinical parameters in patients with Brugada syndrome. We seek to identify non-invasive markers of quinidine effect in patients with Brugada Syndrome which could be used to develop a non-invasive strategy for monitoring medical therapy in these patients and reduce the need for invasive procedures.
Interventions
Hydroquinidine 300mg, oral capsule, twice daily
For 2 weeks
Adherence will be monitored by patient report and tablet return. Serum quinidine levels will also be performed.
This is a non-randomised trial.
Sponsors
Sydney Local Health District
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Diagnosis of Brugada Syndrome
Exclusion criteria
Current treatment with drug known to prolong QT interval Baseline QTc >450msec for men, > 460msec for women Baseline QRS > 130msec Baseline PR >200msec Patients taking medications known to interact with quinidine Known hypersensitivity to quinidine
Outcome results
None listed